Valeant Pharmaceuticals International, Inc. Form 4 December 27, 2010

December 27,	2010									
<b>FORM</b> Check this	box	TATES		ITIES Al hington, 1			COMMISSION	-	PPROVAL 3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							urs per			
(Print or Type Re	esponses)									
1. Name and Address of Reporting Person <u>*</u> ValueAct Holdings, L.P.			2. Issuer Name <b>and</b> Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 435 PACIFIC FLOOR,	(First) (M C AVENUE, 4TH	(Middle) 3. Date of Earliest Transactio (Month/Day/Year)					X_ Director 10% Owner Officer (give titleX_ Other (specify below) below) See remarks			
SAN FRANC	4. If Amendment, Date Original Filed(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li> Form filed by One Reporting Person</li> <li>_X_ Form filed by More than One Reporting</li> </ul>					
							Person			
(City)		Zip)					quired, Disposed of		-	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transactio Code (Instr. 8) Code V	4. Securit mAcquired Disposed (Instr. 3, 4) Amount	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, no par value							26,959,901	I	See footnotes $(1)$ $(2)$	
Reminder: Repo	rt on a separate line f	for each cla	ass of secur	rities benefic	cially owne	ed directly or	•	tion of a	NEC 1474	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. D Sc (I
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Share Units	<u>(3)</u>	12/22/2010		A <u>(4)</u>	614	05/12/2010	05/12/2019	Common Stock, no par value	614	
Restricted Share Units	<u>(3)</u>	12/22/2010		A <u>(4)</u>	723	05/22/2008	05/22/2017	Common Stock, no par value	723	
Restricted Share Units	<u>(3)</u>	12/22/2010		A <u>(4)</u>	728	05/20/2009	05/20/2018	Common Stock, no par value	728	

#### Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
reporting owner runner runness	Director	10% Owner	Officer	Other		
ValueAct Holdings, L.P. 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133	Х			See remarks		
ValueAct Capital Master Fund, L.P. 435 PACIFIC AVENUE 4TH FLOOR SAN FRANCISCO, CA 94133	Х			See remarks		
VA Partners I, LLC 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133	Х			See remarks		
ValueAct Capital Management, L.P. 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133	Х			See remarks		
ValueAct Capital Management, LLC 435 PACIFIC AVENUE, 4TH FLOOR SAN FRANCISCO, CA 94133	Х			See remarks		
ValueAct Holdings GP, LLC 435 PACIFIC AVENUE, 4TH FLOOR	Х			See remarks		

SAN FRANCISCO, CA 94133

### Signatures

VALUEACT HOLDINGS, L.P., By: VALUEACT HOLDINGS GP, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date
VALUEACT CAPITAL MASTER FUND, L.P., By: VA PARTNERS I, LLC, its General Partner, By:/s/ George F. Hamel. Jr., Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date
VA PARTNERS I, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date
VALUEACT CAPITAL MANAGEMENT, L.P., By: VALUEACT CAPITAL MANAGEMENT, LLC, its General Partner, Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date
VALUEACT CAPITAL MANAGEMENT, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date
VALUEACT HOLDINGS GP, LLC, By:/s/ George F. Hamel. Jr., Chief Operating Officer	12/27/2010
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct

(1) Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and the membership interests of ValueAct Capital Management, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.

Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary(2) interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

- (3) Each restricted share unit (RSU) represents a contingent right to receive one share of Common Stock, no par value, of Valeant Pharmaceuticals International, Inc. (the "Common Stock"). The RSUs were awarded to G. Mason Morfit as a Director of the Issuer.
- (4) Represents dividend equivalents accrued on RSUs as a result of a dividend paid on the Common Stock on December 22, 2010.

Under an agreement with ValueAct Capital, G. Mason Morfit is deemed to hold the restricted share units for the benefit of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC

(5) as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.

#### **Remarks:**

-The reporting persons herein may be deemed to be members of a "group" for purposes of the Securities Exchange Act of 1934

-G. Mason Morfit, a member of the management board of ValueAct Holdings GP, LLC, serves on the board of directors of the

Joint Filer Information:

Name: ValueAct Capital Master Fund, L.P. Address:435 Pacific Ave, 4th Floor, San Francisco, CA 94133 Designated Filer: ValueAct Holdings, L.P. Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX) Date of Event Requiring Statement: 12/22/10

Name: VA Partners I, LLC Address:435 Pacific Ave, 4th Floor, San Francisco, CA 94133 Designated Filer: ValueAct Holdings, L.P. Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX) Date of Event Requiring Statement: 12/22/10

Name: ValueAct Capital Management, L.P. Address:435 Pacific Ave, 4th Floor, San Francisco, CA 94133 Designated Filer: ValueAct Holdings, L.P. Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX) Date of Event Requiring Statement: 12/22/10

Name: ValueAct Capital Management, LLC Address:435 Pacific Ave, 4th Floor, San Francisco, CA 94133 Designated Filer: ValueAct Holdings, L.P. Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX) Date of Event Requiring Statement: 12/22/10

Name: ValueAct Holdings GP, LLC Address: 435 Pacific Ave, 4th Floor, San Francisco, CA 94133 Designated Filer: ValueAct Holdings, L.P. Issuer & Ticker: Valeant Pharmaceuticals International, Inc. (VRX) Date of Event Requiring Statement: 12/22/10

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.